ERBB2 and breast cancer: Survival analysis showed that ECD overexpression significantly correlates with poor BC patient survival in the whole cohorts as well as in the hormone receptor-negative, TNBC, and HER2+ subgroups (Fig. 5D to K), supporting and confirming our previous immunohistochemistry (IHC) analysis.